Latest News for: fc receptor

Edit

Bullous Pemphigoid Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, ...

GetNews 12 Mar 2025
VYVGART (efgartigimod PH20 SC) developed by Argenx is an antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor and blocking the IgG recycling process.
  • 1
×